Adalimumab biosimilars now on PBS

And after the first continuing scripts, all will be on streamlined authority

Four adalimumab biosimilars are now available on the PBS, giving Australian rheumatologists the option of prescribing an alternative to AbbVies’s originator, Humira, for the first time.

The new biosimilars are Amgevita (Amgen), Hadlima (MSD), Hyrimoz (Sandoz), and Idacio (Fresenius Kabi) and, like Humira, they’re indicated for severe disease in active rheumatoid arthritis, psoriatic arthritis, active juvenile idiopathic arthritis and ankylosing spondylitis.

The biosimilars are ‘a-flagged’, meaning that they can be substituted for each other and for the originator